Top-line data is expected from two of Ophthotech Corp (NASDAQ: OPHT)'s pivotal Phase III trials in the next month. Leading into the catalyst, which could take the stock either way, Stifel analyst Stephen Willey maintains a Buy rating and $75 price target on the stock, representing about 135 upside potential.
In addition to the firm's bullish price target, Willey provided an assumed negative scenario of $7 per share in the event of negative data and $100 to $120 per share in the event of a positive report.
The analyst acknowledged three necessary warnings against Stifel's scenario:
Distinctions in mechanisms between Ophthotech’s Fostiva and Regeneron Phamaceuticals Inc (NASDAQ: REGN)'s failed rinucumab.
Comparison between “largely uninterruptable” Phase I results.
Phase IIb data on Fostiva lacking anatomical evidence.
Taking the caveats into account, Willey said the current Ophthotech valuation favorably resets the risk/reward profile.
In addition to the firm's bullish price target, Willey provided an assumed negative scenario of $7 per share in the event of negative data and $100 to $120 per share in the event of a positive report.
The analyst acknowledged three necessary warnings against Stifel's scenario:
Distinctions in mechanisms between Ophthotech’s Fostiva and Regeneron Phamaceuticals Inc (NASDAQ: REGN)'s failed rinucumab.
Comparison between “largely uninterruptable” Phase I results.
Phase IIb data on Fostiva lacking anatomical evidence.
Taking the caveats into account, Willey said the current Ophthotech valuation favorably resets the risk/reward profile.
